Add Yahoo as a preferred source to see more of our stories on Google. Johnson & Johnson’s Spravato nasal spray has been approved to treat a major depressive disorder in adults who have had an ...

Johnson & Johnson’s esketamine nasal spray continues to build a body of evidence showing it can go toe-to-toe with tough-to-treat depression. Wednesday, J&J’s Janssen unit rolled out data from the ...

At least 21 million adults in the U.S. have experienced depression. And, while oral antidepressant medications are a common treatment, they don't work for everyone. Now, the Food and Drug ...

TITUSVILLE, N.J., Jan. 21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

Spravato (esketamine) is a nasal spray used for depression and was approved by the FDA in 2019. It is specifically for treatment-resistant depression, meaning depression symptoms that have not gotten ...

Spravato (esketamine) is a prescription drug that’s approved to treat certain forms of depression. Esketamine comes as a nasal spray that you inhale. Specifically, Spravato is approved by the Food and ...

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images. Major ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow. The spray, ...

Spravato (esketamine) is a prescription drug approved to treat specific forms of depression. It comes as a nasal (nose) spray. Spravato is usually given on a dosing schedule that varies by the ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a major ...